They are poor substrates for RFC, and as a result, more effectively reduce growth of folate receptor (FR)- and proton-coupled folate transporter (PCFT)-expressing tumor cells and in human tumor xenografts [196,197]. Here, SLC46A1 is linked to neoplasm.